Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence of Azilsartan Tablets in Chinese Healthy Volunteers
NCT03652792Phase 1Completed
- Sponsor
- Lee's Pharmaceutical Holdings Limited
- Start
- Jan 2018
- Primary completion
- Jun 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of azilsartan in hypertension (HTN) (4 cohorts), sponsored by Lee's Pharmaceutical Holdings Limited. Primary endpoints: Bioequivalence under Fasting Condition at 48 hours and Bioequivalence under Fed Condition at 48 hours. Started Jan 2018; status: completed.
02
Drugs
azilsartan
03
Conditions
hypertension (HTN)
Beyond the preview
Go deeper on NCT03652792.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03652792.